/
Cardiovascular
Cardiovascular Events
3
Pipeline Programs↗
12
Active Trials↗
10
Companies Involved↗
Cardiovascular Events is an early-stage landscape with 3 programs across 10 companies. The most active players are Amgen, Fujian Shengdi Pharmaceutical Co., Ltd.. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
2 of 3 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
41
clinical trials
Completed22 · 54%
Recruiting6 · 15%
Active, not recruiting4 · 10%
Unknown status4 · 10%
Not yet recruiting2 · 5%
Withdrawn2 · 5%
Other1 · 2%
Clinical Trials
Trial Activity
41 trials
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
Recruiting·—·Phase 3·NCT07052799·2,514 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)